AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31221679
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward)
Trial: 31221679
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl) among patients with preoperative CKD
Trial: 31221679
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward) among patients with preoperative CKD
Trial: 27514371
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of solifenacin 5/10 mg + mirabegron 25/50 mg
Trial: 27514371
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of solifenacin 10 mg + mirabegron 25 mg
Trial: 27514371
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of solifenacin 5 mg + mirabegron 50 mg
Trial: 25740286
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with fluorouracil plus EC-P (FEC-P)
Trial: 25740286
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with EC-P
Trial: 25740286
Drug: Standard-interval chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-interval chemotherapy (administered intravenously every 3 weeks) with FEC-P
Trial: 25740286
Drug: Standard-interval chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-interval chemotherapy (administered intravenously every 3 weeks) with EC-P
Trial: 25740286
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy (every 2 weeks)
Trial: 25740286
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of fluorouracil to chemotherapy
Trial: 23328090
Drug: lersivirine 500
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lersivirine 500 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Trial: 23328090
Drug: lersivirine 750
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lersivirine 750 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Trial: 23328090
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Trial: 23328090
Drug: lersivirine 500
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lersivirine 500 mg
Trial: 23328090
Drug: lersivirine 750
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lersivirine 750 mg
Trial: 16435117
Drug: Fixed pharmaceutical
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed pharmaceutical budgets
Trial: 12742982
Drug: Aspirin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (160 mg qd for 7 days)
Trial: 8888744
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (TF) at doses of 25 or 50 micrograms/h
Trial: 6325864
Drug: Nocardia rubra
RxNorm normalized name: Rhodotorula rubra
DrugBank: Rhodotorula rubra (DB10442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocardia rubra cell-wall skeleton (N-CWS) treatment
Trial: 6325864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no N-CWS treatment)
Trial: 31500849
Drug: Remote ischaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5‐min inflation and 5‐min deflation of an automated cuff device)
Trial: 31500849
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only)
Trial: 28230557
Drug: Conventional Dresden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Dresden protocol (3 mW/cm for 30 min, dose 5.4 J/cm)
Trial: 28230557
Drug: Accelerated protocol
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated protocol (30 mW/cm for 3 min 40 s, dose 6.6 J/cm)
Trial: 23700932
Drug: Methyldioxotetrahydropyrimidine sulfonisonicotinoyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldioxotetrahydropyrimidine sulfonisonicotinoyl hydrazide (MSH) at a daily dose of 800-1200 mg for 2-5 months
Trial: 23700932
Drug: MSH on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSH on drug susceptible MBT
Trial: 23700932
Drug: MSH on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSH on drug resistant MBT (isoniazid MIC of 1 mcg/ml)
Trial: 23700932
Drug: MSH on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSH on isoniazid resistant MBT at 10 mcg/ml
Trial: 16121879
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL bupivacaine 0.25% intraperitoneal spray
Trial: 16121879
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL bupivacaine 0.25% intraperitoneal spray mixed with 200 mg ketoprofen
Trial: 16121879
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL bupivacaine 0.25% intraperitoneal spray and intravenous 200 mg ketoprofen
Trial: 16121879
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ketoprofen intravenously
Trial: 11876691
Drug: Low-dose azathioprine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose azathioprine (< 2 mg/kg)
Trial: 10438404
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone (100 mg x 2/day)
Trial: 10438404
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (200 mg x 4/day)
Trial: 7793869
Drug: Cefuroxime axetil,
RxNorm normalized name: Cefuroxime Axetil, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil, 500 mg twice daily for 20 days
Trial: 7793869
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg three times daily for 20 days
Trial: 6383111
Drug: Ergometrine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergometrine 0.25 mg
Trial: 6383111
Drug: Syntocinon 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntocinon 10 mg
Trial: 25844756
Drug: Lurasidone 20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20-60 mg
Trial: 25844756
Drug: Lurasidone 80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 80-120 mg
Trial: 21515398
Drug: Beta-glucan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan (3 g/d)
Trial: 19112336
Drug: Etodolac (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (400 mg/d)
Trial: 16014819
Drug: Behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral and nutrition treatment (nutrition counseling and child behavioral management training for parents)
Trial: 11789748
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement
Trial: 11789748
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement
Trial: 1314337
Drug: Methoxamine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine (intravenous administration)
Trial: 1314337
Drug: Norepinephrine (NE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE, intravenous administration)
Trial: 3908131
Drug: iodopropylidene glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodopropylidene glycerol (IPG-Organidin), two tablets four times daily
Trial: 30620140
Drug: Preoperative topical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate (10 mg/ml) and nepafenac (1 mg/ml)
Trial: 30620140
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative anti-inflammatory treatment
Trial: 30620140
Drug: Preoperative topical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate and nepafenac
Trial: 23321182
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg orally once daily
Trial: 23321182
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg orally twice daily
Trial: 19087678
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus continuous renal replacement therapy (CRRT)
Trial: 16238122
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g of xanthan gum with test meal (ham sandwich - 90 kcal)
Trial: 9952140
Drug: Air therapy
RxNorm normalized name: Amlactin Foot Repair Therapy 15% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air therapy (control)
Trial: 1971660
Drug: Cholestyramine or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine or Pravastatin treatment
Trial: 30048324
Drug: Low-dose contrast
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose contrast enhanced CT
Trial: 28940815
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, pantoprazole 40 mg twice daily for 10 days)
Trial: 28940815
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (amoxicillin 1000 mg with pantoprazole 40 mg twice daily for 5 days, followed by clarithromycin 500 mg with metronidazole 500 mg and pantoprazole 40 mg twice daily for 5 days)
Trial: 28940815
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy in clarithromycin-resistant strains
Trial: 28940815
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy in clarithromycin-resistant strains
Trial: 22868243
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m² twice daily on days 1‐14 (Arm A)
Trial: 22868243
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m² twice daily on days 1‐14, oxaliplatin 100 mg/m² on day 1 initially, 130 mg/m² for subsequent cycles (Arm B)
Trial: 19053049
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg three times a day) with a 1,400 Kcal/day diet plus vitamin E (800 IU) daily
Trial: 19053049
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus vitamin E (800 IU) daily
Trial: 11157603
Drug: Moxifloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin, 400 mg/d for 10 days
Trial: 11157603
Drug: Amoxicillin, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, 1,000 mg tid for 10 days
Trial: 25829373
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g/8 h)
Trial: 9593156
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g/8 h) plus Gentamicin (4 mg/kg daily)
Trial: 7921936
Drug: Modified Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Needle Suspension (MNS)
Trial: 2848900
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of oral acyclovir, twice daily for one year
Trial: 2848900
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for one year
Trial: 29636004
Drug: Central venous
RxNorm normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central venous administration of sufentanil (group CV)
Trial: 29636004
Drug: Peripheral venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral venous administration of sufentanil (group PV)
Trial: 26628268
Drug: Internet-delivered six-lesson
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered six-lesson 10-week cognitive behavioural therapy (iCBT) intervention for PTSD
Trial: 23987791
Drug: Aprepitant plus
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone)
Trial: 18771232
Drug: Intensive glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose-lowering therapy (HbA1c < 6%) in ACCORD trial
Trial: 18771232
Drug: Intensive glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose-lowering therapy (HbA1c ≤ 6.5%, modified release gliclazide as main treatment) in ADVANCE trial
Trial: 18771232
Drug: Intensive glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose-lowering therapy in VA-Diabetes trial
Trial: 15705991
Drug: Inhaled colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled colistin (75 mg in 4 mL saline solution)
Trial: 10564839
Drug: Aerosolized ABT-431
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized ABT-431 (5 mg); C(max) was 13.3±0.9 ng/ml and AUC(0-24) was 33.2±10.6 h ng/ml in dogs.
Trial: 10564839
Drug: Oral inhalation
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation of ABT-431 (dosage levels between 3.3 and 13.2 mg); demonstrated rapid absorption and dose-dependent increase in AUC.
Trial: 1746653
Drug: AIDS education,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIDS education, HIV antibody test, and test results
Trial: 6269770
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, and Adriamycin (VOCA)
Trial: 6269770
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, Adriamycin (VOCA) plus low-dose (40 mg/m2) cisplatin (VOCAP)
Trial: 25918277
Drug: PediQUEST Memorial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PediQUEST Memorial Symptom Assessment Scale (PQ‐MSAS) administered 920 times
Trial: 25918277
Drug: Mild cancer‐directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild cancer‐directed therapy in the final 12 weeks of life
Trial: 23602942
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) program, 12 sessions
Trial: 21347803
Drug: Tacrolimus 3
RxNorm normalized name: Tacrolimus 300 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 3 mg once daily for 52 weeks
Trial: 19081190
Drug: Topical high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical high concentration (10%) capsaicin
Trial: 19081190
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three GCH1 SNPs
Trial: 15638906
Drug: Vardenafil 5
RxNorm normalized name: vardenafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 5 mg
Trial: 16422973
Drug: Vardenafil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (all doses)
Trial: 8510708
Drug: Inhaled heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled heparin (1000 U per kilogram)
Trial: 6412606
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (20 mg)
Trial: 3548314
Drug: Aminoglutethimide and
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide and hydrocortisone plus Estrace 2 mg b.i.d. sublingually for 3 days before and on the day of chemotherapy
Trial: 3548314
Drug: Aminoglutethimide and
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide and hydrocortisone plus cyclic chemotherapy (control group)
Trial: 27039081
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR 40 mg/28 days
Trial: 27039081
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR 20 mg/28 days
Trial: 11339108
Drug: hydrogen reduced
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrogen reduced iron plus ascorbic acid (15 mg)
Trial: 3588053
Drug: Piperacillin 600
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin 600 mg/kg/day
Trial: 3588053
Drug: Piperacillin 900
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin 900 mg/kg/day
Trial: 3588053
Drug: Piperacillin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (total daily dosages)
Trial: 28497478
Drug: Dapoxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine (30 mg)
Trial: 28497478
Drug: Combined dapoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dapoxetine (30 mg) with sildenafil citrate (50 mg)
Trial: 28169811
Drug: Pediatric Peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric Peripheral Intravenous Infiltration Scale (PIV Scale)
Trial: 17922612
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (2 g/d)
Trial: 15540741
Drug: Bicalutamide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (150 mg)
Trial: 11386498
Drug: Inositol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol (up to 18 g/day)
Trial: 7956987
Drug: Oat gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat gum (2.9 g beta-glucan)
Trial: 3602212
Drug: Bromocriptine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (single dose)
Trial: 23239139
Drug: Losmapimod, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod, 7.5 mg BID for 28 days
Trial: 21689371
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 7500 IU twice daily until birth or 34 weeks
Trial: 16940833
Drug: Seven‐valent pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven‐valent pneumococcal conjugate vaccine
Trial: 9180362
Drug: THC (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (lower dose)
Trial: 9180362
Drug: THC (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (higher dose)